What is GLEAMER?
Based in Paris, France, GLEAMER is at the forefront of applying artificial intelligence to enhance radiological diagnostics. The company's technology aims to improve the accuracy and efficiency of medical imaging analysis, providing crucial support to radiologists and healthcare providers. Its focus on AI in radiology positions it within the rapidly expanding HealthTech sector, a field attracting substantial investment due to its potential to revolutionize patient care and operational workflows in healthcare.
How much funding has GLEAMER raised?
GLEAMER has raised a total of $38.2M across 2 funding rounds:
Series A
$8.7M
Series B
$29.5M
Series A (2020): $8.7M with participation from Macsf, XAnge, Majycc eSanté Invest, Elaia, and Crista Galli Ventures
Series B (2023): $29.5M led by XAnge, Heal Capital, Bpifrance, and Supernova Invest
Key Investors in GLEAMER
Macsf
MACSF is a French mutual insurance provider focused on healthcare professionals, offering a broad spectrum of financial and insurance services. Their involvement suggests a strategic alignment with the healthcare ecosystem.
XAnge
XAnge is a European venture capital firm specializing in early-stage investments, providing capital and expertise to technology startups. Their participation indicates a belief in GLEAMER's innovative potential.
Heal Capital
Heal Capital is a European venture capital firm dedicated to HealthTech and AI, focusing on mission-driven startups. Their investment highlights GLEAMER's strong position within the HealthTech innovation space.
What's next for GLEAMER?
The recent major strategic investment signifies a pivotal moment for GLEAMER, likely enabling the company to accelerate its product development, expand its market reach, and further solidify its technological leadership in AI-powered radiology solutions. This capital infusion is expected to fuel innovation, potentially leading to new product offerings or enhancements to existing platforms. The company's continued access to substantial funding suggests strong investor confidence in its business model and its capacity to scale operations effectively within the competitive MedTech landscape.
See full GLEAMER company page
